Effects of Mycobacterium bovis BCG, bacterial lipopolysaccharide and hydrocortisone on the development of immunity to Plasmodium berghei.
D000818:Animals; D000962:Antimalarials / Q000494:pharmacology; D004338:Drug Combinations / Q000494:pharmacology; D006854:Hydrocortisone / Q000494:pharmacology*; D007111:Immunity, Cellular; D008070:Lipopolysaccharides / Q000494:pharmacology*; D008288:Malaria / Q000276:immunology*; D008297:Male; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008815:Mice, Inbred Strains; D009163:Mycobacterium bovis / Q000276:immunology*; D010962:Plasmodium berghei / Q000276:immunology*; D011739:Pyrimethamine / Q000494:pharmacology; D013413:Sulfadoxine / Q000494:pharmacology
D000962:Antimalarials; D004338:Drug Combinations; D008070:Lipopolysaccharides; C001205:fanasil, pyrimethamine drug combination; D013413:Sulfadoxine; D006854:Hydrocortisone; D011739:Pyrimethamine